In a groundbreaking move to combat serious infections, CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has announced a $1 million investment in Zeteo Tech, a biotech company that is pioneering an innovative noninvasive diagnostic test for lower respiratory tract infections (LRTIs) using exhaled breath.

Based in Maryland, Zeteo Tech will utilize this funding to advance its BreathBiomics platform. This cutting-edge technology employs matrix-assisted laser desorption and ionization mass spectrometry (MALDI-MS) to analyze breath aerosol samples, enabling the distinction between viral and bacterial infections, identifying active infections versus mere colonization, and evaluating antibiotic susceptibility.

The potential of using breath samples, especially from children, is remarkable. This method presents a less invasive alternative to traditional sampling techniques like bronchoalveolar lavage or sputum collection, which can be particularly discomforting for young patients suspected of having LRTIs. With pneumonia claiming the lives of 700,000 children under five annually, the development of a fast and noninvasive diagnostic test is critical. It promises to expedite diagnoses, minimize unnecessary antibiotic use, and tailor treatments for drug-resistant infections.

Targeting Groundbreaking Diagnostics for Lung Infections

This award is part of CARB-X’s latest funding initiative aimed at innovative diagnostic solutions for LRTIs. As highlighted by Erin Duffy, PhD, the R&D chief at CARB-X, "Accurate and swift diagnosis of lower respiratory tract infections is a significant clinical challenge—especially in critical care environments. We are eager to observe how Zeteo's technology evolves through its early-stage development and what insights it might generate to enhance patient care."

Since its establishment in 2016, CARB-X has backed 118 pioneering R&D projects focused on preventing, treating, and diagnosing antibiotic-resistant infections. Notably, 22 of these have progressed to or completed clinical trials, marking significant strides in the global fight against antibiotic resistance.